Executive interview at Edison

In this interview, CFO Michael Hunt explains the core technology of ReNeuron’s business, the stem cell science it is developing, optimising and harnessing to create therapeutic products. He discusses the recently reported early Phase II clinical trial data for its CTX stem cell therapy in stroke and why this has given ReNeuron the confidence to commence a pivotal Phase II/III clinical trial in 2017. Finally, he also discusses expected newsflow resulting from the remainder of ReNeuron’s pipeline – critical limb ischaemia (Phase I) and hRPC or retinitis pigmentosa (Phase I/II).

ReNeuron receives regulatory and ethical approvals to commence clinical trial in UK with stem cell therapy candidate for critical limb ischaemia – the second major disease target for the Company’s lead CTX stem cell therapy candidate

Guildford, UK, 26 March 2013:  ReNeuron is pleased to announce that it has received regulatory and ethical approvals to commence a Phase I clinical trial in the UK with its ReN009 stem cell therapy programme targeting the major unmet medical need, critical limb ischaemia (CLI).

Section: News